Cargando…
Survival benefit with adjuvant chemotherapy in stage III microsatellite-high/deficient mismatch repair colon cancer: a systematic review and meta-analysis
Clinical observations have demonstrated that microsatellite instability-high (MSI-H) and/or deficient MMR (dMMR) status are associated with favorable prognosis and no benefit from 5-Fluorouracil (5-FU)-based adjuvant chemotherapy in patients with resected stage II colorectal cancer (CRC). This study...
Autores principales: | Tomasello, Gianluca, Ghidini, Michele, Galassi, Barbara, Grossi, Francesco, Luciani, Andrea, Petrelli, Fausto |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8776729/ https://www.ncbi.nlm.nih.gov/pubmed/35058539 http://dx.doi.org/10.1038/s41598-022-05065-6 |
Ejemplares similares
-
Timing of Adjuvant Chemotherapy and Survival in Colorectal, Gastric, and Pancreatic Cancer. A Systematic Review and Meta-Analysis
por: Petrelli, Fausto, et al.
Publicado: (2019) -
Extramedullary Hematopoiesis in Mismatch Repair Deficient Colon Cancer Patient on Adjuvant Chemotherapy
por: De Leo, Edward K, et al.
Publicado: (2021) -
Duration of FOLFOX Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer With Deficient Mismatch Repair
por: Hu, Huabin, et al.
Publicado: (2020) -
Stage III deficient mismatch repair colon patients get greater benefit from earlier starting oxaliplatin-based chemotherapy regimen
por: Zhan, Yixiang, et al.
Publicado: (2023) -
Impact of Use of Gastric-Acid Suppressants and Oral Anti-Cancer Agents on Survival Outcomes: A Systematic Review and Meta-Analysis
por: Indini, Alice, et al.
Publicado: (2020)